NCT05778253Recruiting
The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC
Circulating Tumor DNA (ctDNA) Dynamic Monitoring Plus Artificial Intelligence (AI)-Based Pathology Predict the Efficacy of Chemoimmunotherapy in Resectable Lung Squamous Cell Carcinoma (LSCC)
Source: ClinicalTrials.gov · Last updated 21 Mar 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this observational study is to explore whether ctDNA dynamic monitoring plus AI-based pathology can more effectively predict the therapeutic effect of neoadjuvant chemoimmunotherapy for resectable lung squamous cell carcinoma, so as to accurately guide clinical diagnosis and treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 23 Feb 2023
- Start date
- 23 Mar 2023
- Primary completion date
- 23 Sept 2028
- Lead sponsor
- Second Xiangya Hospital of Central South University
- Diseases
- Lung cancer
- NCT number
- NCT05778253
What you commit to
- Study type: Observational
- Planned participants: 50
- From 23 Mar 2023 to the primary completion date, 23 Sept 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with solid organ or blood system transplantation
- Previous use of CTLA-4, PD-1, or PD-L1 immune checkpoint inhibitors
- Patients who have undergone other clinical drug trials
Other illness
- Patients with interstitial lung disease
- Patients with acute or chronic infectious disease
Other
- Patients who cannot understand the content of the experiment and cannot cooperate, and those who refuse to sign the informed consent form
- Non-squamous NSCLC
- Unresectable IIIa-IIIb tumor
- Pregnant and lactating women
Who the study is looking for
- Histopathology or cytology confirmed the lung squamous cell carcinoma
- Age ranging from 18 to 75
- Agree to participate in this study and sign an informed consent form
- Treatment-naive tumor
- According to the American Joint Committee on Cancer (AJCC) eighth edition of the Lung Cancer Staging Manual, the clinical stage is stage II-IIIb resectable or potentially resectable tumor
- Sufficient tissue/blood samples are available to meet research requirements
- The ECOG PS score is 0-1
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Thoracic Surgery, Second Xiangya Hospital of Central South University, China Coordinator of this site? Confirm its status | Changsha | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.